Ankyra Therapeutics, a clinical-stage biotechnology company pioneering anchored drug conjugate technology for cancer and other diseases, today announced the publication online of Part 1 results from ...

Takeda ( TSE:4502/NYSE:TAK) announced the completion of the 7-year pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial evaluating its dengue vaccine, QDENGA ® ▼(Dengue ...

Cribriform morphology strongly predicts 15-year metastasis in patients with prostate cancer, and radiotherapy with ...

MaaT Pharma Presents Updated Preclinical Data at SITC Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity ...

ASPEN-06 data to be presented at SITC demonstrates that evorpacept drove durable clinical benefit across all efficacy measures in HER2+ gastric ...

Cobenfy, the first new schizophrenia drug in 50 years, offers early insights that could pave the way for more personalized ...

Consortia led by Pakistani oil and gas companies to carry out geophysical and geological studies in Indus and Makran basins ...

Findings further demonstrate the effectiveness of Roche's approved medicines in advancing treatment standards for people with blood disorders Data from innovative pipeline signals progress ...

COP30 delegates may have to stay at ‘love motels’ as a dearth of affordable accommodation prices people out of the summit — and logistical woes are just the tip of the iceberg ...

Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a ...

Q3 2025 Earnings Call November 6, 2025 8:30 AM ESTCompany ParticipantsVipin Garg - President, CEO & DirectorLinda Richardson ...

“The data we will present at this year’s ASH meeting ... 19-20 Multiple myeloma Cevostamab: Clinical and exploratory biomarker analysis from the phase Ib CAMMA-1 study shows investigational cevostamab ...